News

Extending market exclusivity and responding properly to the volume of recent patent expiries are critical to the sustainability of pharmaceutical corporations. In the midst of the 2012-2019 patent cliff, the period during which market exclusivity for top-selling biologics is jeopardized, pharmaceutical corporations have been...